Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published online in The Lancet Infectious Diseases.
The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
“The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well.”
Dr. Donald Krogstad
“The clinical trial results are extraordinarily encouraging,” said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine. “Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
The Latest on: Malaria
- Kenya: Malaria Cases Go Up as Over 1,000 Test Positive on October 21, 2017 at 2:02 pm
More than 1,000 people have tested positive for Malaria in Marsabit, northern Kenya, weeks after the deadly disease killed more than 26 people in the expansive region. A report handed to the country's Health Cabinet Secretary Cleopa Mailu also showed that ... […]
- Kenya’s fight against malaria in numbers on October 21, 2017 at 11:56 am
A raft of preventive measures, including use of insecticide treated bednets in high-risk areas, has helped cut the prevalence rate of malaria in Kenya even though it still ranks among top five causes of death in the country. Countrywide, malaria prevalence ... […]
- Pollution kills more people each year than war, AIDS, and malaria combined on October 21, 2017 at 9:11 am
A landmark new study on the public health impacts of global pollution found that toxic air, water, and soil are responsible for the deaths of nine million people each year, more than the number that die from war, hunger, malaria, and AIDS — combined. […]
- Could A Plant End Malaria? Researchers Think There Is Hope on October 20, 2017 at 12:20 pm
Researchers have found a promising treatment for malaria — and it's the same plant that Asians have been drinking as a tea for centuries. Doctors in Africa are now prescribing tea made from Artemisia annua, which is native to China, to halt the ... […]
- Sickle cell anemia treatment does not increase malaria risk in Africa on October 20, 2017 at 10:28 am
The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study. Sickle cell anemia (SCA) is an inherited disorder characterized by abnormal red ... […]
- Malaria Outbreak Kills 4 at Kenyan Refugee Camp on October 20, 2017 at 8:50 am
A malaria outbreak has killed at least four people at a refugee camp in northwestern Kenya, according to local residents and health officials. Hundreds of people have come down with the infectious disease at the Kalobeyei refugee complex in Kenya's Turkana ... […]
- Pollution Is Killing More People Than AIDS, Malaria and TB Combined on October 20, 2017 at 7:18 am
We’ve always known pollution was bad. But a new study says that pollution actually causes more deaths than AIDS, malaria and tuberculosis combined. Josh King has the story (@abridgetoland). […]
- Could the Artemisia plant be the cure for malaria? on October 19, 2017 at 4:00 pm
Thanks to the Belgian organisation’s work, several residents of Luebo have tested Artemisia tea. Our Observer Jean Tshibinda Kazadi manages a hospital in Luebo called CPC Hospital. Usually, the staff there treats patients with quinine and artesunate ... […]
- Report: Pollution Kills 3 Times More than AIDS, TB And Malaria Combined on October 19, 2017 at 3:30 pm
Exposure to polluted air, water and soil caused nine million premature deaths in 2015, according to a report published Thursday in The Lancet. The causes of death vary — cancer, lung disease, heart disease. The report links them to pollution, drawing ... […]
- Malaria Diagnostics Market Regulations, Size, Share and Competitive Landscape Outlook to 2025: Credence Research on October 18, 2017 at 7:36 am
The global malaria diagnostics market was valued at US$ 210.2 Mn in 2016, and is expected to reach US$ 308.2 Mn by 2025, expanding at a CAGR of 4.2% from 2017 to 2025. According to the latest market report published by Credence Research, Inc. “malaria ... […]
via Google News and Bing News